Moderna Secures FDA Approval for First mRNA Flu Vaccine for Older Adults

Moderna (NASDAQ: MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA (mRNA-1010), its first mRNA-based influenza vaccine for adults aged 50 and older. This development represents a critical milestone in the company's strategy to reduce its reliance on COVID-19 vaccines and expand its mRNA technology platform into new applications. The vaccine received full approval for adults aged 50 to 64, and accelerated approval for those 65 and older, requiring post-marketing studies to confirm clinical benefit in this population.

Moderna's path to mFLUSIVA approval was initially challenging, marked by a “refusal-to-file letter” from the FDA in February 2026, which declined to review the application. This was due to concerns regarding the methodology of the comparator vaccine used in the company's trials. However, Moderna successfully changed the FDA's stance by submitting a revised plan and conducting an additional trial. In June 2026, the FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended that the vaccine's benefits outweighed its risks, paving the way for the final approval.

This approval offers Moderna a potential new growth engine as demand for its COVID-19 vaccines wanes. Investment bank Jefferies estimates that U.S. sales for mFLUSIVA could reach approximately $750 million by 2030, encompassing both the standalone flu vaccine and a COVID-flu combination vaccine. However, company management has stated that its 2026 revenue guidance does not include any contribution from this new flu vaccine. Wall Street analysts also anticipate that meaningful sales will not materialize before the 2027-2028 flu season, as commercial purchasing contracts for seasonal flu vaccines are typically signed early each year.

Moderna is targeting up to 10% revenue growth for 2026, though this growth is primarily expected from existing products, such as international COVID-19 vaccine sales and strategic partnerships. The company's mRNA technology offers faster production timelines compared to traditional flu vaccines (2-3 months versus six months), potentially allowing for quicker adaptation to circulating flu strains. This speed is particularly relevant in situations like the World Health Organization's recommendation earlier this year to update viral strains in 2026 flu vaccines.

In a broader economic and political context, there has been increased scrutiny of mRNA technology and skepticism from some federal health officials and political figures. For instance, in 2025, the U.S. Department of Health and Human Services (HHS) canceled approximately $500 million in federal contracts for mRNA vaccine development. Despite this, the approval of mFLUSIVA demonstrates the mRNA platform's potential against infectious diseases beyond COVID-19. However, gaining market share in the flu vaccine market, long dominated by established players like Sanofi and GSK, may take time. The company is also developing other products, including mCOMBRIAX, a COVID-flu combination vaccine approved in the European Union, and oncology therapies.

According to market expectations, while mFLUSIVA's long-term revenue contribution could be significant, its near-term impact on MRNA stock may be limited. Despite the company reporting Q2 revenue of $145 million, exceeding analyst estimates, and a narrower net loss, a setback in its norovirus vaccine candidate recently impacted stock performance. Analysts will closely monitor future clinical data and FDA approvals to fully unlock the commercial potential of Moderna's expanding mRNA pipeline. The company plans to make mFLUSIVA available to select U.S. retailers in the coming weeks, ahead of the 2026-2027 respiratory virus season.